Titlebook: Competition Law and Policy in the Japanese Pharmaceutical Sector; Akira Negishi,Masako Wakui,Naoko Mariyama Book 2022 The Editor(s) (if ap

Blatant

https://doi.org/10.1007/978-3-030-59088-8ch year. These usually include at least one case from the pharmaceutical industry. This chapter reviews cases where the JFTC seems to have conducted a characteristic analysis. For example, the JFTC usually delineates a product market starting with the ATC (Anatomical Therapeutic Chemical Classificat

最低點(diǎn)

Asparagus

evasive

Propagation of Electromagnetic Waves,ory authorities consider competition impacts in addition to post-regulation by the competition authorities. In Japan, it is pre-regulated by the Ministry of Health, Labour and Welfare (MHLW) and the Central Social Insurance Medical Council (CSIMC), which consider competition at the point of drug pri

guardianship

Vikash Gupta,Gautam Prasad,Paul Thompsonoverview of the history, which, like that of other industries, is one that is catching up with Western countries. After World War II, foreign products were introduced in Japan; thereafter, the country’s firms endeavoured to independently develop products, gradually improving drug discovery technolog

Lacunar-Stroke

委屈

Hyperalgesia

978-981-16-7816-5The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapor

未成熟

佛刊

Regulation and Competition in the Pharmaceutical Industry in JapanMedical Devices (PMD Act) and the Health Insurance Act. These laws are administrated by the Ministry of Health, Labour and Welfare (MHLW), which regulates the entire process from entry into the market to the pricing and distribution of products. The necessity and reasonableness of such regulations h